SCHEMBL6773485

SCHEMBL6773485

CC(=O)c1cc(NC(=O)OC(C)(C)C)ccc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA9 Q16790 1/20 0.46
RXFP1 Q9HBX9 1/20 0.45
CYP17A1 P05093 4/20 0.43
NAMPT P43490 1/20 0.43
ACHE P22303 1/20 0.42
BACE1 P56817 1/20 0.42
SYK P43405 1/20 0.42
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RORC P51449 2/20 0.41
HTT P42858 1/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19233276 0.88 KDM4E (0.46) CA12CA1CA9RXFP1CYP17A1
SCHEMBL941486 0.84 HPGD (0.51) CA12CA1CA9CYP17A1NAMPT
SCHEMBL30681937 0.84 HPGD (0.51) CA12CA1CA9CYP17A1NAMPT
SCHEMBL7497345 0.84 ACHE (0.54) CA12CA1CA9RXFP1CYP17A1
SCHEMBL6816071 0.82 CA12 (0.48) CA12CA1CA9RXFP1CYP17A1
SCHEMBL29537539 0.82 CA12 (0.48) CA12CA1CA9RXFP1CYP17A1
SCHEMBL7081255 0.82 LMNA (0.49) RXFP1CYP17A1NAMPTKDM4ENPC1
SCHEMBL3202901 0.81 HTT (0.62) ALDH1A1GAAKDM4ENPC1RAB9A
SCHEMBL1440700 0.81 CA12 (0.47) CA12CA1CA9RXFP1CYP17A1
SCHEMBL1094945 0.81 CA12 (0.47) CA12CA1CA9RXFP1CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015961-A1 ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-01-19 US disclosed
US-6703387-B2 STYRYLBENZODIAZEPINES HOFFMANN-LA ROCHE INC. 2004-03-09 US disclosed
EP-1299364-A1 BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE F. HOFFMANN-LA ROCHE AG (CH) 2003-04-09 EP disclosed
US-20020128262-A1 Inhibitors of HPV E1 helicase enzyme F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2002-09-12 US disclosed
WO-2002000632-A1 BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE F. HOFFMANN-LA ROCHE AG (CH) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015961-A1 ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY BACE1, BACE2, APP CA12 1896/4885CA1 100/4885CA9 1623/4885
US-20020128262-A1 Inhibitors of HPV E1 helicase enzyme DHX15, DHX35, DHX36 CA12 3661/4885CA1 1872/4885CA9 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.